Literature DB >> 11476989

Gene therapy for pancreatic cancer--current and prospective strategies.

C M Halloran1, P Ghaneh, J P Neoptolemos, E Costello.   

Abstract

Pancreatic ductal adenocarcinoma is one of the most common causes of cancer death in the developed world. Long-term survival is currently only achieved through surgical resection. Most patients have locally advanced or metastatic disease at the time of diagnosis and are therefore not amenable to resection, whilst chemotherapy and radiotherapy are by and large ineffective. Gene therapy offers an alternative to current adjuvant strategies. With approximately two-thirds of all gene therapy trials worldwide directed at cancer, the gene therapy approaches that are currently being explored for pancreatic cancer are specifically examined. Gene delivery systems, genetic targets, and combined gene delivery with chemotherapy are discussed in the context of pancreatic cancer treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11476989     DOI: 10.1016/s0960-7404(01)00011-1

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  4 in total

Review 1.  Trials of gene therapy for pancreatic carcinoma.

Authors:  Christopher M Halloran; Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Curr Gastroenterol Rep       Date:  2005-06

2.  Risk Factors of Reoperation After Pancreatic Resection.

Authors:  Heather G Lyu; Gaurav Sharma; Ethan Brovman; Julius Ejiofor; Aparna Repaka; Richard D Urman; Jason S Gold; Edward E Whang
Journal:  Dig Dis Sci       Date:  2017-03-24       Impact factor: 3.199

3.  Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer.

Authors:  Jing Wang; Xiao-Xuan Lu; Dao-Zhen Chen; Shu-Feng Li; Li-Shan Zhang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 4.  Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy.

Authors:  Michail Galanopoulos; Aris Doukatas; Filippos Gkeros; Nikos Viazis; Christos Liatsos
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.